financetom
Business
financetom
/
Business
/
Manappuram block deal: 11% equity exchanged, Quinag likely a seller
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Manappuram block deal: 11% equity exchanged, Quinag likely a seller
Aug 24, 2023 3:11 AM

Early trade today witnessed a flurry of activity in the shares of Manappuram, with multiple block trades making waves in the market. A substantial sum of Rs 1,404.92 crore, representing 11.69 percent of the company's equity, changed hands in these transactions. Notably, a single block worth Rs 1,188.81 crore, accounting for a 9.9 percent stake, was a prominent part of this significant equity exchange.

Share Market Live

NSE

The transactions were executed at a per-share price of Rs 141.85. Current shareholding records reveal that Quinag Acquisitions (FPI) Ltd (Apex) now commands a substantial 9.9 percent stake in Manappuram as of June 2023. In the days leading up to this significant equity exchange, there had been a buzz in the market regarding the impending block trades. Such anticipation underscores the market's watchful eye on pivotal events that can potentially influence the trajectory of a company's growth and its valuation in the market.

In today’s session, the shares of Manappuram are down nearly 3 percent. The share price at this point is slightly above the price at which the blocks were executed.

In the first quarter of this fiscal, the company reported earnings better than expectations with total assets under management rising nearly 21 percent year-on-year and 5 percent on a sequential basis. The core business, that is Gold loan, saw a healthy growth of more than 4 percent in its AUM on a sequential basis. On the bottom line, the company saw a growth of 85 percent and on the top line (NII), it saw a rise of 38 percent year-on-year.

Also Read: Ramkrishna Forgings bags Rs 156 cr contract to supply transmission and engine components

(Edited by : Vivek Dubey)

First Published:Aug 24, 2023 12:11 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Street Color: Delta Air Lines Cancelled 50 Flights as of Noon Wednesday
--Street Color: Delta Air Lines Cancelled 50 Flights as of Noon Wednesday
Jul 24, 2024
03:11 PM EDT, 07/24/2024 (MT Newswires) -- Price: 43.05, Change: -0.56, Percent Change: -1.30 ...
Disney, unions reach tentative pact, avoiding strike at Disneyland
Disney, unions reach tentative pact, avoiding strike at Disneyland
Jul 24, 2024
ANAHEIM, California, July 24 (Reuters) - Unions representing 14,000 Disneyland employees said on Wednesday they had reached a tentative labor agreement with Walt Disney Co ( DIS ) , averting a work stoppage at the California theme park. The new, three-year agreement, which includes wage increases and other benefits for park employees, whom Disney ( DIS ) calls cast members,...
Wayfair Q2 Results Seen Muted on Soft Demand for Home Furnishings, Wedbush Says
Wayfair Q2 Results Seen Muted on Soft Demand for Home Furnishings, Wedbush Says
Jul 24, 2024
03:11 PM EDT, 07/24/2024 (MT Newswires) -- Wayfair ( W ) Q2 results are expected to be muted amid soft demand for home furnishings and prospects for conservative guidance on Q3 sales growth, Wedbush said Wednesday in a report. We see modest downside risk to our and consensus' [Q2] sales growth estimate, Wedbush said. Wayfair's ( W ) tight cost...
Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker
Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker
Jul 24, 2024
Vigil Neuroscience Inc ( VIGL ). released interim data on Wednesday from its ongoing Phase 1 clinical trial of VG-3927 in healthy volunteers. VG-3927 is a novel small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease (AD) patients, including some who carry TREM2 and other disease-associated variants. The interim...
Copyright 2023-2026 - www.financetom.com All Rights Reserved